From Research findings to Therapeutic opportunity:
The study presented here suggests that Honokiol, by increasing the expression of its target genes, it may: (i) increase the expression of CADM1; (ii) decrease BMI1 translocation; (iii) increase tumor suppressor INK4a/p16 expression; and (iv) restore chemosensitivity in drug-resistant Human cancers (Fig 1.).
[easy_payment currency=”USD”]
Thereby, it may inhibit proliferation, chemoresistance and apoptosis of cancer cells. Thus, pharmacological formulations encompassing “Honokiol or its analogues or Honokiol in combination with any of known anti-cancer drugs” (fig. 2) may be used to inhibit cancer progression.
Figure 1 Honokiol, isolated from Magnolia grandiflora/dealbata/obovata/officinalis, increases the expression of CADM1, inhibits BMI-1 translocation, increases tumor suppressor INK4a/p16 expression and inhibits chemoresistance via up-regulation of its target gene
Figure 2. Honokiol
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed information: How Honokiol increases the expression of CADM1, and INK4a/p16?
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $5
For purchase and payment details, you may reach us at info@genomediscovery.org
References:
Citation: Boominathan, L., Natural product-derived therapy for overcoming chemoresistance in Human cancers: Honokiol increases the expression of CADM1, decreases BMI1 translocation, increases tumor suppressor INK4a/p16 expression and restores chemosensitivity in drug-resistant Human cancers via down regulation of its target gene, 18/December/2016, 11.01 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org or newbioideas.com
Courtesy: When you cite drop us a line at info@genomediscovery.org